Session Information
Date: Monday, June 20, 2016
Session Title: Parkinsonism, MSA, PSP (secondary and parkinsonism-plus)
Session Time: 12:30pm-2:00pm
Location: Exhibit Hall located in Hall B, Level 2
Objective: To evaluate the impact of comorbidities and compliance iniciatives on treatment efficacy in patients with Parkinson’s disease.
Methods: In the year 2014 we included 52 symptomatic consecutive patients (mean age 58.3±5.7 years) with early Parkinson’s disease and initial pharmacotherapy of levodopa+dopamine agonists and neuroprotection. Physical examination, laboratory tests, CT scan were performed at baseline. We examined compliance initiatives every month during 1-year period after 1st admission to clinic.
Results: 22(42.3%) patients were strictly compliant with pharmacologic therapy, diet, life style changes, 30/52 patients (56.7%) were non-compliant with no improvement in treatment. At baseline prevalence of depressive disorders, dysthymia, severity of gate and mental health disorders were comparable in both groups. 1-year treatment in compliant group resulted in a daily off time reduction (−43.7%; from 2.71±0.71 to 1.52±0.44 h/day; 95%CI from 0.83 to 1.55, p=0.0001). Among non-compliant patients forgetfulness was in 14(46.7%) patients, lack of financial support to buy medications was in 11(36.7%), adverse effects in 3(10%) cases, patients’ reluctance to take medication for long lime was in 6(20%) patients. We found differences in comorbidities in groups presented in Table.
Parameters | Compliant group, n=22 | Non-compliant group, n=30 | P value |
Arterial hypertension | 6(27.3%) | 9(36.6%) | 1.0 |
Orthostatic hypotension | 4(18%) | 6(20%) | 1.0 |
Hyperlipidemia | 11(50%) | 27(90%) | 0.034 |
Coronary artery disease | 9(41%) | 25(83.3%) | 0.027 |
Type 2 diabetes | 1(4.5%) | 9(36.6%) | 0.0316 |
Atrial fibrillation | 1(4.5%) | 4(13.3%) | 1.0 |
Ventricular arrhythmia | 1(4.5%) | 9(36.6%) | 0.0316 |
Congestive heart failure | 7(31.8%) | 16(53.3%) | 0.162 |
Conclusions: Compliant group showed decline of motor symptoms and preserve quality of life. Comorbidities such as coronary artery disease, diabetes and hyperlipidemia showed differences in compliant initiatives.
To cite this abstract in AMA style:
A.V. Shalaeva, N.A. Dadabaeva, R.M. Allanov, M.B. Bozorboev, E. Shalaeva. Impact of comorbidities and compliance initiatives in management of patients with early Parkinson’s disease [abstract]. Mov Disord. 2016; 31 (suppl 2). https://www.mdsabstracts.org/abstract/impact-of-comorbidities-and-compliance-initiatives-in-management-of-patients-with-early-parkinsons-disease/. Accessed December 10, 2024.« Back to 2016 International Congress
MDS Abstracts - https://www.mdsabstracts.org/abstract/impact-of-comorbidities-and-compliance-initiatives-in-management-of-patients-with-early-parkinsons-disease/